Microbot Medical Net Income vs. Total Debt

MBOT Stock  USD 1.74  0.06  3.33%   
Taking into consideration Microbot Medical's profitability measurements, Microbot Medical may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in March. Profitability indicators assess Microbot Medical's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
1991-03-31
Previous Quarter
-3.5 M
Current Value
-3.6 M
Quarterly Volatility
2.8 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Price To Sales Ratio is likely to drop to 302.36 in 2026. Days Sales Outstanding is likely to drop to 37.34 in 2026. At this time, Microbot Medical's Total Other Income Expense Net is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 172 K in 2026, whereas Net Loss is likely to drop (10.8 M) in 2026. Gross Profit Margin is likely to gain to 0.98 in 2026, despite the fact that Gross Profit is likely to grow to (77.8 K).
For Microbot Medical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Microbot Medical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Microbot Medical utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Microbot Medical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Microbot Medical over time as well as its relative position and ranking within its peers.
Check out Correlation Analysis.
For more information on how to buy Microbot Stock please use our How to Invest in Microbot Medical guide.By analyzing Microbot Medical's earnings estimates, investors can diagnose different trends across Microbot Medical's analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Microbot Medical is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Microbot Medical is projected to generate -0.085 in earnings per share on the 31st of December 2026. Microbot Medical earnings estimates show analyst consensus about projected Microbot Medical EPS (Earning Per Share). It derives the highest and the lowest estimates based on Microbot Medical's historical volatility. Many public companies, such as Microbot Medical, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Microbot Medical's earnings estimates, investors can diagnose different trends across Microbot Medical's analyst sentiment over time as well as compare current estimates against different timeframes.
Is there potential for Health Care Equipment & Supplies market expansion? Will Microbot introduce new products? Factors like these will boost the valuation of Microbot Medical. Expected growth trajectory for Microbot significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Microbot Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.44)
Return On Assets
(0.20)
Return On Equity
(0.32)
Investors evaluate Microbot Medical using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Microbot Medical's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Microbot Medical's market price to deviate significantly from intrinsic value.
Understanding that Microbot Medical's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Microbot Medical represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Microbot Medical's market price signifies the transaction level at which participants voluntarily complete trades.

Microbot Medical Total Debt vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Microbot Medical's current stock value. Our valuation model uses many indicators to compare Microbot Medical value to that of its competitors to determine the firm's financial worth.
Microbot Medical is regarded third in net income category among its peers. It is rated below average in total debt category among its peers . At this time, Microbot Medical's Net Loss is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Microbot Medical by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Microbot Total Debt vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Microbot Medical

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(11.44 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Microbot Medical

Total Debt

 = 

Bonds

+

Notes

 = 
111 K
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Microbot Total Debt vs Competition

Microbot Medical is rated below average in total debt category among its peers. Total debt of Health Care industry is now estimated at about 161.96 Million. Microbot Medical adds roughly 111,000 in total debt claiming only tiny portion of equities under Health Care industry.
Total debt  Revenue  Capitalization  Valuation  Workforce

Microbot Medical Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Microbot Medical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Microbot Medical will eventually generate negative long term returns. The profitability progress is the general direction of Microbot Medical's change in net profit over the period of time. It can combine multiple indicators of Microbot Medical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Operating Income-10.5 M-9.9 M
Income Before Tax-10.3 M-10.8 M
Total Other Income Expense Net209.3 K219.8 K
Net Loss-10.3 M-10.8 M
Income Tax Expense163.8 K172 K
Net Loss-13.2 M-13.8 M
Non Operating Income Net Other730.5 K802.2 K
Net Loss-15.1 M-15.9 M
Interest Income243.8 K256 K
Net Interest Income209.3 K219.8 K
Change To Netincome1.2 M1.5 M
Net Loss(0.66)(0.69)
Income Quality 0.89  0.94 
Net Income Per E B T 1.15  0.80 

Microbot Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Microbot Medical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Microbot Medical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Microbot Medical's important profitability drivers and their relationship over time.

Microbot Medical Earnings per Share Projection vs Actual

Use Microbot Medical in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Microbot Medical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Microbot Medical will appreciate offsetting losses from the drop in the long position's value.

Microbot Medical Pair Trading

Microbot Medical Pair Trading Analysis

The ability to find closely correlated positions to Microbot Medical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microbot Medical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microbot Medical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microbot Medical to buy it.
The correlation of Microbot Medical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microbot Medical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microbot Medical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microbot Medical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Microbot Medical position

In addition to having Microbot Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Market Neutral Funds Thematic Idea Now

Market Neutral Funds
Market Neutral Funds Theme
Funds or Etfs that invest in both long and short positions of different entities to enhance returns from broad market movements over time. The Market Neutral Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Market Neutral Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Microbot Stock Analysis

When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.